Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melflufen for relapsed and refractory multiple myeloma.
Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodríguez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG. Oriol A, et al. Among authors: gullbo j. Expert Opin Investig Drugs. 2020 Oct;29(10):1069-1078. doi: 10.1080/13543784.2020.1808884. Epub 2020 Sep 29. Expert Opin Investig Drugs. 2020. PMID: 32924646 Free article. Review.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Rowinsky EK, et al. Among authors: gullbo j. Invest New Drugs. 2020 Oct;38(5):1448-1453. doi: 10.1007/s10637-020-00915-4. Epub 2020 Mar 3. Invest New Drugs. 2020. PMID: 32125598 Free PMC article. Clinical Trial.
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.
Mateos MV, Bladé J, Bringhen S, Ocio EM, Efebera Y, Pour L, Gay F, Sonneveld P, Gullbo J, Richardson PG. Mateos MV, et al. Among authors: gullbo j. J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120. J Clin Med. 2020. PMID: 32992506 Free PMC article. Review.
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J. Wickström M, et al. Among authors: gullbo j. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029544 Free PMC article. Review.
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J. Berglund Å, et al. Among authors: gullbo j. Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10. Invest New Drugs. 2015. PMID: 26553306 Clinical Trial.
In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M, Strese S, Wickström M, Larsson R, Enblad G, Gullbo J. Delforoush M, et al. Among authors: gullbo j. BMC Cancer. 2016 Apr 4;16:263. doi: 10.1186/s12885-016-2299-9. BMC Cancer. 2016. PMID: 27044263 Free PMC article.
87 results